GlaxoSmithKline (NYSE:GSK) Stock Rating Reaffirmed by JPMorgan Chase & Co.

GlaxoSmithKline (NYSE:GSK)‘s stock had its “neutral” rating reaffirmed by research analysts at JPMorgan Chase & Co. in a research report issued on Tuesday, MarketBeat Ratings reports.

Other equities analysts have also issued research reports about the company. Cowen reiterated a “hold” rating and issued a $45.00 price target on shares of GlaxoSmithKline in a research report on Monday, June 10th. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Thursday, April 25th. Finally, Morgan Stanley reiterated an “underweight” rating on shares of GlaxoSmithKline in a research report on Monday, June 17th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $42.66.

Shares of GSK stock opened at $39.68 on Tuesday. The company’s 50-day moving average price is $40.88. GlaxoSmithKline has a fifty-two week low of $36.41 and a fifty-two week high of $42.47. The company has a market capitalization of $99.84 billion, a PE ratio of 12.56, a P/E/G ratio of 1.96 and a beta of 0.71. The company has a debt-to-equity ratio of 7.86, a current ratio of 0.71 and a quick ratio of 0.48.



GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.14. GlaxoSmithKline had a return on equity of 175.45% and a net margin of 13.84%. The business had revenue of $10.04 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Sell-side analysts expect that GlaxoSmithKline will post 2.91 EPS for the current year.

In related news, Director Plc Glaxosmithkline purchased 333,333 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was acquired at an average price of $15.00 per share, for a total transaction of $4,999,995.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 10.00% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. D Orazio & Associates Inc. boosted its position in GlaxoSmithKline by 200.0% during the 1st quarter. D Orazio & Associates Inc. now owns 600 shares of the pharmaceutical company’s stock worth $25,000 after acquiring an additional 400 shares during the period. Berman Capital Advisors LLC boosted its position in GlaxoSmithKline by 58.1% during the 2nd quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock worth $26,000 after acquiring an additional 241 shares during the period. Financial Gravity Wealth Inc. boosted its position in GlaxoSmithKline by 62.7% during the 2nd quarter. Financial Gravity Wealth Inc. now owns 799 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 308 shares during the period. Princeton Global Asset Management LLC acquired a new stake in GlaxoSmithKline during the 1st quarter worth about $37,000. Finally, Reilly Financial Advisors LLC boosted its position in GlaxoSmithKline by 36.7% during the 1st quarter. Reilly Financial Advisors LLC now owns 950 shares of the pharmaceutical company’s stock worth $36,000 after acquiring an additional 255 shares during the period. Hedge funds and other institutional investors own 11.26% of the company’s stock.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

See Also: Oversold

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.